Arecor presents positive data from phase I clinical trial of ultra-concentrated ultra-rapid acting insulin AT278
- AT278 delivers significantly accelerated early PK/PD profile compared with NovoRapid® in people with Type 2 Diabetes and high BMI
AT278 ultra-concentrated ultra-rapid acting insulin demonstrates superiority in Phase I Clinical Trial in overweight and obese people with type 2 diabetes
AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery
Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump
Arecor and TRx Biosciences establish research collaboration to develop Oral Glp-1 with enhanced bioavailability
Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability Collaboration focused on overcoming th
Arecor announces launch of Ogluo® in the Netherlands
Launch builds on continued pan-European commercial roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK.
Arecor granted key european patent extending protection for insulin products, AT278 and AT247
Cambridge, UK - Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a patent (EP3618840) protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247.
Arecor announces expansion of existing specialty hospital formulation collaboration
Cambridge - Arecor Therapeutics, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Arecor appoints Dr Helen Parris as Senior Vice President, Commercial And General Manager of Tetris Pharma Ltd
Cambridge, UK - Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, is pleased to announce the appointment of Dr. Helen Parris as Senior Vice President, Commercial and General Manager of the Group’s subsidiary company, Tetris Pharma Ltd ("Tetris Pharma”), effective Monday 15 January 2024.
Arecor signs co-development and exclusive licence option agreement with leading global medical products company for in-house speciality hospital product
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
Arecor continues collaboration with Lilly
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
First product incorporating Arecor’s Arestat Technology, AT220, launches in Europe
First commercial sale triggers milestone payment and future royalties to Arecor
Arecor announces positive pre-IND meeting with FDA for novel ready-to-use medicine AT307 licensed to Hikma
Cambridge, UK - Arecor, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces further progress from Hikma in the development of ready-to-use ("RTU") injectable medicine AT307, following a recent positive pre-investigational new drug application (pre-IND) meeting between Hikma and the US Food and Drug Administration (FDA).
Arecor to collaborate with top 10 global pharmaceutical company
Arecor expands its global partnerships through collaboration to develop an enhanced antibody formulation
Arecor Announces Additional Agreement with Leading Biopharmaceutical Company
(“Arecor” or the “Group”)
Arecor granted key patents in Europe and China to protect proprietary Insulin products
Patents further strengthen Group’s extensive patent portfolio protecting its Arestat™ technology and innovative insulin products, AT278 and AT247
Arecor presents positive data from US phase I clinical trial Of ultra-rapid acting insulin candidate At247 delivered via insulin pump at Ada annual meeting
Cambridge, UK - Arecor Therapeutics plc - the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that positive results from its second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, have been shared in a poster presentation at the American Diabetes Association (ADA) 83rd Scientific Sessions meeting, being held…
US patent granted protecting proprietary formulations of monoclonal antibodies
Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market
Arecor appoints Dr. Manjit Rahelu as Chief Business Officer
Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A
First patient dosed in second phase I clinical trial of AT278 ultra-concentrated, ultra-rapid acting insulin candidate
Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to enable healthier lives, announces that the first patient has been dosed in its Phase I clinical trial investigating AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate,
Arecor granted patents in India and the United States protecting proprietary formulations of differentiated biopharmaceutical products
Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics
Arecor announces publication of phase 1 data for AT278 in diabetes care
Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control
Arecor announces transfer of AT307 to Hikma
License milestone to develop and commercialise ready-to-use medicine achieved. Arecor regains rights to AT282 following portfolio review at Hikma.
Arecor granted key patent In Japan and South Korea to protect proprietary insulin products At247 and At278
The granted patents further strengthen the Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio